###begin article-title 0
###xml 58 66 <span type="species:ncbi:9606">Patients</span>
Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer
###end article-title 0
###begin p 1
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 505 506 505 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 571 572 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 780 781 780 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 953 954 953 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 963 967 963 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1056 1057 1056 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
###xml 845 853 <span type="species:ncbi:9606">patients</span>
###xml 916 924 <span type="species:ncbi:9606">patients</span>
###xml 995 1003 <span type="species:ncbi:9606">patients</span>
###xml 1066 1074 <span type="species:ncbi:9606">Patients</span>
###xml 1137 1145 <span type="species:ncbi:9606">patients</span>
###xml 1225 1233 <span type="species:ncbi:9606">patients</span>
The aim of the current study was to determine the clinical significance according to the subtypes of epidermal growth factor receptor (EGFR) mutations and presence of KRAS mutations in operable non-small-cell lung cancer (NSCLC). We sequenced exons 18-21 of the EGFR tyrosine kinase domain and examined mutations in codons 12 and 13 of KRAS in tissues of patients with NSCLC who had undergone surgical resection. EGFR mutations were more frequent in never-smokers than smokers (33% vs. 14%, respectively; p=0.009) and in females than in males (31% vs. 16%, respectively; p=0.036). Mutations in exon 18-19 and 20-21 were found in 10 and 22 patients, respectively. Never-smokers and broncho-alveolar cell carcinoma features were positively associated with a mutation in exon 18-19 (p=0.027 and 0.016, respectively). The five-year survival rate in patients with a mutation in exons 18-19 (100%) was higher than that in patients without such mutation (47%; p=0.021). KRAS mutations were found in 16 patients (12%) and were not related to the overall survival (p=0.742). Patients with an EGFR mutation in exons 18-19 had better survival than patients without such mutation. Subtypes of EGFR mutations may be prognostic factors in patients undergoing curative resection.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
Lung cancer is the leading cause of cancer mortality worldwide (1). The overall 5-yr survival for lung cancer is approximately 15% and has improved only marginally over the past 30 yr despite the progress of modern chemotherapy (2). Therefore, new treatment strategies are needed to improve the prognosis of this dismal disease.
###end p 3
###begin p 4
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 491 492 491 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 850 851 846 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1032 1033 1028 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1035 1036 1031 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1038 1039 1034 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
Aberrant signaling from the epidermal growth factor receptor (EGFR) is known to be important in the development and progress of non-small-cell lung cancer (NSCLC) (3). Several agents designed to inhibit EGFR tyrosine kinase such as gefitinib and erlotinib showed good tolerability and antitumor activity in NSCLC (4, 5). Somatic mutations in the region of EGFR encoding the tyrosine kinase domain have been identified to be an important factor determining the sensitivity to these drugs (6, 7). The tyrosine kinase domain of EGFR consists of N and C lobes. Until now, mutations had been found in EGFR exons 18-21, which encode the N lobe and part of the C lobe. Mutations in the different exons target structures around the ATP-binding cleft of EGFR, including the phosphate-binding loop (P-loop), the alphaC-helix, and the activation loop (A-loop) (8). In theory, all mutations could result in conformational changes and increased activity of the protein, as well as changes in its sensitivity to tyrosine kinase inhibitors (TKI) (6, 7, 9).
###end p 4
###begin p 5
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
Recent studies have reported inconsistent results for EGFR mutations as a prognostic factor in cancer. The Canadian BR.21 trial reported that the presence of EGFR mutations confers no survival benefit on patients treated with erlotinib, whereas the results of the TRIBUTE trial found that EGFR mutations are a good prognostic factor (10-14). We surmised that there might be subgroups of EGFR mutations showing different survival rates.
###end p 5
###begin p 6
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
KRAS mutations, which could result in resistance to EGFR inhibitors, are frequently reported changes in the EGFR signaling pathway in NSCLC (15, 16). These mutations are detected in 15-20% of NSCLC patients (16). A recent meta-analysis suggested that KRAS mutations might be another prognostic factor for overall survival in NSCLC (17).
###end p 6
###begin p 7
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
We undertook this study to identify a subgroup of EGFR mutations and to define the prognostic role of KRAS mutations involved in the overall survival of patients with resected NSCLC.
###end p 7
###begin title 8
PATIENTS AND METHODS
###end title 8
###begin title 9
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 9
###begin p 10
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
Tumor tissues were procured from patients who had undergone surgical resection at the Korea Cancer Center Hospital from May 1995 to May 2004. One hundred and thirty three formalin-fixed paraffin-embedded tissues were available for the analysis. All patients had pathologically proven localized NSCLC. All pathology was reviewed using the WHO classification (18). Pure broncho-alveolar cell carcinoma (BAC), BAC with focal invasion, and adenocarcinoma with BAC features were considered as one entity (adenocarcinoma with BAC features) (19, 20). The study protocol was reviewed and approved by the institutional review board of the Korea Cancer Center Hospital.
###end p 10
###begin title 11
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
DNA Sequencing for EGFR and KRAS mutations
###end title 11
###begin p 12
###xml 236 237 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 711 715 691 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1039 1043 1019 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1179 1181 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
DNA was extracted from formalin-fixed paraffin-embedded tissue sections of 10 microm thickness. DNA (100 ng) was amplified in 20 microL of reaction solution containing 2 microL of 10x buffer (Roche, Mannheim, Germany), 1.7-2.5 mM/L MgCl2, 250 microM deoxynucleoside triphosphate, 2.5 units of DNA polymerase (Roche), and 0.3 microM each primer pair for EGFR (exon 18: forward, 5'-TCCAAATGAGCTGGCAAGTG-3'and reverse, 5'-TCCCAAACACTCAGTGAAACAAA-3'; exon 19: forward, 5'-ATGTGGCACCATCTCACAATTGCC-3'and reverse, 5'-CCACACAGCAAAGCAGAAACTCAC-3'; exon 20: forward, 5'-CATTCATGCGTCTTCACCTG-3'and reverse, 5'-CATATCCCCATGGCAAACTC-3'; exon 21: forward, 5'-GCTCAGAGCCTGGCATGAA-3'and reverse, 5'-CATCCTCCCCTGCATGTGT-3') or KRAS (codons 12-13: forward, 5'-TTATGTGTGACATGTTCTAAT-3'and reverse, 5'-AGAATGGTCCTGCACCAGTAA-3'; codon 61: forward, 5'-TCAAGTCCTTTGCCCATTTT-3'and reverse, 5'-TGCATGGCATTAGCAAAGAC-3'). Fragments were amplified with a 5 min initial denaturation at 94℃, followed by 30 cycles of 1 min at 94℃, 1 min at 57℃ (EGFR mutation) or 55℃ (KRAS mutation), and 1 min at 72℃, with a final 10 min extension at 72℃. Purification and sequencing were performed as previously described (13).
###end p 12
###begin title 13
Statistical analysis
###end title 13
###begin p 14
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 377 378 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
The primary endpoint was overall survival, the definition of which was the time from diagnosis to death from any cause. The secondary endpoint was disease-free survival, which was defined as the time from diagnosis to the earliest occurrence of relapse or death from any cause. Overall and disease-free survivals were calculated by the Kaplan-Meier method (21). The Pearson chi2 or Fisher's exact test was used for categorical variables. Mutation type (wild type, mutations in exons 18-19 or 20-21) was correlated with sex, smoking history, and pathology using multinomial logistic regression with the mutation type as the categorical dependent variable. A log-rank test was performed for the univariate analysis of survival.
###end p 14
###begin p 15
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
Recursive partitioning using RPART, with exponential scaling for survival data, was applied to classify patients according to their death risk (22, 23). The splitting process stopped when the number of splits was two to avoid overfitting.
###end p 15
###begin p 16
###xml 49 50 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
S-PLUS(R) was used for statistical analyses. All p values reported are the results of two-sided tests, and values less than 0.05 were considered significant.
###end p 16
###begin title 17
RESULTS
###end title 17
###begin title 18
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end title 18
###begin p 19
###xml 58 65 58 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 462 463 462 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 528 529 528 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 682 683 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 791 792 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 801 805 799 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 945 946 943 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1026 1027 1024 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1114 1118 1112 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 645 653 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
The baseline characteristics of the patients are shown in Table 1. Sixty-three (47%) patients were male. The median age was 63 yr. The predominant pathology was adenocarcinoma (99 patients, 74%). Never-smokers comprised 52% of patients. The proportions of stage I, II, and III cancers were 36%, 17%, and 47%, respectively. EGFR mutations were detected in 24% of patients. The mutation rate was higher in never-smokers than in smokers (33% vs. 14%, respectively; p=0.009) and in females than in males (31% vs. 16%, respectively; p=0.036). The frequency of EGFR mutations was not significantly greater in younger (<50 yr) than in older (>/=50 yr) patients (33% vs. 23%, respectively; p=0.322) or in patients with adenocarcinomas than in those with other histologies (27% vs. 5%, respectively; p=0.139). KRAS mutations were detected in 16 of 133 (12%) patients, and were detected more frequently in males than in females (19% vs. 6%, respectively; p=0.018), more often in smokers than in never-smokers (19% vs. 6%, respectively; p=0.022). Neither pathology nor age was a significant factor predicting the presence of KRAS mutations.
###end p 19
###begin title 20
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Types of EGFR and KRAS mutations
###end title 20
###begin p 21
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 72 79 <span type="species:ncbi:9606">patient</span>
###xml 99 106 <span type="species:ncbi:9606">patient</span>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 186 193 <span type="species:ncbi:9606">patient</span>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 277 284 <span type="species:ncbi:9606">patient</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 376 383 <span type="species:ncbi:9606">patient</span>
Mutations in codons 12 and 13 of KRAS were found in 16 patients and one patient, respectively (one patient had a double mutation). G12D (nine patients) was the most common mutation (one patient also carried G13D). G12C (two patients) and G12V (two patients) were detected. One patient carried G12S, and G12A was observed in two patients. There was no mutation in codon 61. No patient had a tumor in which both EGFR and KRAS were mutated.
###end p 21
###begin p 22
###xml 45 52 45 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 269 276 <span type="species:ncbi:9606">patient</span>
###xml 298 305 <span type="species:ncbi:9606">patient</span>
###xml 331 338 <span type="species:ncbi:9606">patient</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 389 396 <span type="species:ncbi:9606">patient</span>
EGFR mutations were detected in 32 patients (Table 2). Mutations in exon 20 were most frequent (16 patients). P772_H773insPR in exon 20 was detected in 11 patients. All mutations present in exon 19 were deletion types; del K745_E749 (four patients), del A750_K757 (one patient), del E746_A750 (one patient), and del L747_P753 (one patient). L858R in exon 21 was found in six patients. One patient carried two mutations, in exon 18 and exon 21 (G719D and L861Q, respectively).
###end p 22
###begin p 23
###xml 409 410 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 649 650 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 794 801 794 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
Multinomial logistic regression was used to compare two subgroups of EGFR mutations in the different exons with those of the wild type (the double mutation in exons 18 and 21 was considered to be a mutation in exon 18). The odds ratio was calculated with the wild type as the reference group. Non-small-cell lung cancer with a mutation in exon 18 or 19 was positively associated with never-smokers (OR, 10.7; p=0.027) and BAC features (OR, 5.93; p=0.016). All cases with a mutation in exon 18 or 19 were adenocarcinoma. Females also showed a positive relationship with mutations in exons 18 or 19, but the association was not significant (OR, 4.41; p=0.068). Compared with mutations in exons 18-19, mutations in exons 20-21 did not show a significant association with never-smokers or females (Table 3).
###end p 23
###begin title 24
Types of EGFR mutations were associated with disease-free and overall survival
###end title 24
###begin p 25
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 224 230 224 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 430 431 430 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 816 817 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 826 833 826 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2A</xref>
###xml 991 992 991 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1001 1008 1001 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2B</xref>
###xml 1015 1019 1015 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1104 1105 1104 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1138 1144 1138 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 753 761 <span type="species:ncbi:9606">patients</span>
###xml 958 966 <span type="species:ncbi:9606">patients</span>
The median follow-up time was 29 months. By May 2005, the numbers of observed relapses and deaths were 83 and 54, respectively. The presence of EGFR mutations was not significantly associated with overall survival (p=0.27) (Fig. 1). Interestingly, we found that the five-year survival rate (5YSR) for mutations in exons 18-19 (5YSR, 100%) was higher than that for mutations in exons 20-21 (5YSR, 57%) or the wild type (5YSR, 44%; p=0.056). For the analysis of different demographic features and statistical power, the types of mutations in the different exons were collapsed to mutations in exons 18-19 and others. There was no significant difference in disease-free survival between these two groups; the median disease-free survival was 45 months for patients with mutant exons 18-19 and 26 months for the others (p=0.143) (Fig. 2A). The presence of a mutation in exons 18-19 was a significant prognostic factor for overall survival (5YSR, 100% vs. 47% in patients without such mutations; p=0.021) (Fig. 2B). The KRAS mutation was not a prognostic factor for disease-free survival or overall survival (p=0.371 and 0.742, respectively) (Fig. 3).
###end p 25
###begin p 26
###xml 84 91 84 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4A</xref>
###xml 136 140 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 936 943 934 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4B</xref>
###xml 1090 1091 1088 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
We applied recursive partitioning to construct a classification model for survival (Fig. 4A). Age (<50 vs. >/=50 yr), stage, pathology, KRAS mutation, and exon site of EGFR mutation (designated Ex 18, Ex 19, Ex 20, Ex 21, and wild type) were used in the model. The standardized event rate, which is a special case of the event rate in the Poisson model for censored data with exponential scaling, was set to one for the entire sample at the first node. The classification tree started at the top where 54 of the 133 total patients developed events. The model chose the exon site of the mutation for the first split and cancer stage for the second. The resulting terminal nodes (node 1, node 2, and node 3) were groups with mutations in Ex 18-19, stage I-II, and stage III according to increasing standardized event rates (0.17, 0.89, and 1.41, respectively). The observed five-year survival rates were 100%, 53%, and 46%, respectively. Fig. 4B shows the Kaplan-Meier estimates of overall survival according to each node. The survival rates of the three groups were significantly different (p=0.026).
###end p 26
###begin title 27
DISCUSSION
###end title 27
###begin p 28
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
Recently, the BR.21 trial reported the survival benefits of erlotinib as a second-line therapy, in which the subgroup of never-smokers displayed better survival (11). The results of a subset analysis in the TRIBUTE trial showed a survival gain for never-smokers when treated with chemotherapy and erlotinib (24). It seems clear that some subgroups might respond to TKI or show a survival benefit.
###end p 28
###begin p 29
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
Most studies have based their analyses on the assumption that all types of EGFR mutations have the same prognostic significance in terms of overall survival. Mutations in exon 18 are associated with the P-loop. Deletion of exon 19 occurs just downstream from a lysine residue at a critical position for ATP binding, and L858R mutations occur adjacent to the DFG motif, which stabilizes the A-loop. All types of mutations, including these mutations, could lead to conformational changes that might theoretically result in a response to TKI (9, 25). However, in most studies, no structural modeling or biochemical analysis has been performed for novel mutations. Furthermore, not all investigators analyzed exons 18-21 of EGFR (13, 14).
###end p 29
###begin p 30
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
Shigematsu et al. reported a mutation in exon 20 that is found in 9% of patients with EGFR mutations (26). In our study, 16 of 32 patients carried a mutation in exon 20, which is a relatively high proportion compared with those reported previously. It should be noted that there was a preponderance of early-stage cancers and adenocarcinomas in our study population. Our results indicate that mutations in exon 20 were more common in females (10 patients), never-smokers (10 patients), and those with adenocarcinomas (13 patients), which is consistent with the known demographic features of EGFR mutations. Racial differences could be a possible cause.
###end p 30
###begin p 31
###xml 256 258 256 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1000 1002 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1007 1009 1007 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1011 1013 1011 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1665 1667 1665 1667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 2164 2166 2164 2166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 665 673 <span type="species:ncbi:9606">patients</span>
###xml 702 710 <span type="species:ncbi:9606">patients</span>
###xml 774 782 <span type="species:ncbi:9606">patients</span>
###xml 970 978 <span type="species:ncbi:9606">patients</span>
###xml 1785 1793 <span type="species:ncbi:9606">patients</span>
The proportions of mutations in exons 18-19 among EGFR mutants have varied in previous studies. Cappuzzo et al. reported a frequency of 47% (seven of 15 mutations), and found that gene amplification is a more important factor in survival than is mutation (14). The BR.21 trial showed that 40% of mutations occurred in exons 18-19 (16 of 40 mutations) (10). Of the other studies that showed a survival benefit for TKI, Han et al. reported that 65% of mutations occurred in exons 18-19 (11 of 17 mutations) and Eberhard et al. reported that 69% of mutations occurred in exons 18-19 (20 of 29 mutations) (12, 13). In another study, which reported a better response in patients with deletion mutations (16 patients with deletions in exons 18-19 mutation) and better survival in patients with mutant EGFR, exon 18-19 mutations comprised 61% of all mutations (27). The proportion of exon 18-19 mutations appears to be higher in studies that show a survival benefit for TKI in patients with EGFR mutations (10, 12-14, 27). Therefore, the inconsistent results of previous studies regarding EGFR mutations might be due to the varying proportions of exon 18-19 mutations among the mutant EGFRs examined. This could lead to different analyses of the putative 'EGFR mutation' as a prognostic factor. The current study suggests that the exonal site of EGFR muations and stage were more important prognostic factors than pathology. Our results also show a positive association between never-smokers and exon 18-19 mutations, compared with exon 20-21 mutations. The TRIBUTE molecular study found that EGFR mutations were a prognostic factor in NSCLC, but the BR.21 study did not (10). Both studies reported better survival for never-smokers. These studies did not undertake molecular analysis of all patients. Therefore, the discrepancy for EGFR mutations but the consistency for never-smokers could be explained if never-smokers have a greater tendency to carry exon 18-19 mutations. In addition, different demographic features according to BAC feature and smoking history may explain the results of another study to observe better response in the BAC subtype and never-smoker (20).
###end p 31
###begin p 32
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 914 915 914 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1632 1633 1632 1633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 1348 1356 <span type="species:ncbi:9606">patients</span>
###xml 1517 1525 <span type="species:ncbi:9606">patients</span>
###xml 1562 1570 <span type="species:ncbi:9606">patients</span>
Most previous studies for EGFR mutations examined patients with advanced-stage cancers, whereas we performed this study on localized tumors. The subgroup analysis of TRIBUTE showed that EGFR mutations did not confer a survival benefit in combination with chemotherapy, but did confer better survival with no relationship to the type of treatment (12). This suggests that EGFR mutations themselves are a prognostic factor for survival. We postulated that survival differences caused by EGFR mutations could be observed in resected NSCLC. Shigematsu et al. found no survival difference according to the presence of EGFR mutations, which was consistent with our study (26). They evaluated the survival outcome between the L858R mutation and exon 19 mutation. Contrasting with our results, patients with the L858R mutation appeared to achieve better survival although the difference was not statistically significant (p=0.05). It should be considered that this study involved a heterogeneous group including advanced-stage cancers and presented the results of univariate analysis. In addition, its study population consisted of various ethnicities and the proportion of adenocarcinoma was lower than our study. These differences might have led to different results for overall survival according to mutational types of EGFR. In the current study, some patients (n=15) received gefitinib in relapse. There was no difference in terms of response to gefitinib according to mutational sites (data not shown). Even when these patients were excluded in survival analysis, patients with mutations in exon 18-19 showed better overall survival (p=0.045).
###end p 32
###begin p 33
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
It is not clear whether the various types of mutant EGFRs affect the survival of patients with tumors by different signal transduction pathways. Although both deletion of exon 19 and L858R mutation activated EGFR by a common pathway (AKT and STAT), EGF-induced phosphorylation of Y845, one of autophosphorylation sites in EGFR, was observed only in cell lines with the L858R mutation (28). Some investigators have reported that phosphorylated Y845 regulates cell survival by another downstream pathway (29). We hypothesize that mutations on either side of the alphaC-helix of EGFR (mutations in exons 18-19 and exons 20-21) cause different conformational changes in EGFR that lead to the activation of various downstream pathways. A definitive explanation of the variations in survival according to the exon site of the EGFR mutation requires further studies.
###end p 33
###begin p 34
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
In conclusion, the present study demonstrated better survival for NSCLC patients with mutations in exons 18-19. This suggests that survival may differ according to the exon sites of the EGFR mutation. Our results, together with those of previous studies, should be interpreted with caution because the numbers of patients with mutations were small and the studies were performed retrospectively. Further laboratory studies of the downstream pathways involved and analysis of the actual crystal structures of the EGFR mutants are anticipated. A large prospective study is required to confirm these findings.
###end p 34
###begin article-title 35
Global cancer statistics in the year 2000
###end article-title 35
###begin article-title 36
One hundred years of lung cancer
###end article-title 36
###begin article-title 37
Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology
###end article-title 37
###begin article-title 38
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial
###end article-title 38
###begin article-title 39
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial)
###end article-title 39
###begin article-title 40
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
###end article-title 40
###begin article-title 41
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
###end article-title 41
###begin article-title 42
Receptor tyrosine kinase inhibitors as anti-angiogenic agents
###end article-title 42
###begin article-title 43
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
###end article-title 43
###begin article-title 44
Erlotinib in lung cancer - molecular and clinical predictors of outcome
###end article-title 44
###begin article-title 45
Erlotinib in previously treated non-small-cell lung cancer
###end article-title 45
###begin article-title 46
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
###end article-title 46
###begin article-title 47
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
###end article-title 47
###begin article-title 48
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
###end article-title 48
###begin article-title 49
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
###end article-title 49
###begin article-title 50
###xml 99 104 <span type="species:ncbi:9606">human</span>
Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung
###end article-title 50
###begin article-title 51
###xml 40 48 <span type="species:ncbi:9606">patients</span>
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
###end article-title 51
###begin article-title 52
The new World Health Organization classification of lung tumours
###end article-title 52
###begin article-title 53
Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma
###end article-title 53
###begin article-title 54
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer
###end article-title 54
###begin article-title 55
Nonparametric estimation from incomplete observations
###end article-title 55
###begin article-title 56
A comparison of estimated proportional hazards models and regression trees
###end article-title 56
###begin article-title 57
Tree-structured proportional hazards regression modeling
###end article-title 57
###begin article-title 58
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
###end article-title 58
###begin article-title 59
The conformational plasticity of protein kinases
###end article-title 59
###begin article-title 60
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
###end article-title 60
###begin article-title 61
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
###end article-title 61
###begin article-title 62
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
###end article-title 62
###begin article-title 63
Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II
###end article-title 63
###begin p 64
Kaplan-Meier plots of overall survival according to EGFR mutations.
###end p 64
###begin p 65
###xml 23 24 23 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 53 54 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Kaplan-Meier plots of (A) disease-free survival and (B) overall survival according to the presence of EGFR mutations in exons 18-19.
###end p 65
###begin p 66
###xml 30 34 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Overall survival according to KRAS mutations by Kaplan-Meier method.
###end p 66
###begin p 67
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 182 183 182 183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
(A) The final tree fitted by recursive partitioning using an exponential scaling method. The standardized event rate and events/total number of observations per subgroup are given. (B) Kaplan-Meier plots of overall survival according to three different nodes.
###end p 67
###begin p 68
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient characteristics
###end p 68
###begin p 69
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 109 116 <span type="species:ncbi:9606">patient</span>
Types of EGFR mutations. Numbers in parentheses indicate the numbers of patients with the mutations. (*) one patient carried two different mutations
###end p 69
###begin p 70
Clinical characteristics according to exonal sites of EGFR mutations
###end p 70

